Recordati

Historical price data

Founded in 1926 by Giovanni Recordati, this Milan-based pharmaceutical group has evolved from a family pharmacy into a global pharmaceutical force with operations in ~150 countries. The company focuses on both common conditions affecting large populations and rare diseases with limited treatment options, operating through integrated R&D, manufacturing, and commercial capabilities. With a market valuation of approximately €10.5 billion and strong presence in Europe, the company continues expanding its specialty and rare disease portfolio while maintaining its commitment to 'unlocking the full potential of life.'

Integrated pharmaceutical operations spanning R&D, manufacturing, and commercialization with focus on both common diseases and rare conditions through two chemical plants and seven manufacturing sites worldwide.

35 drugs in pipeline, 5 in Phase 3

Competes with major pharmaceutical companies in specialty care and rare diseases, differentiating through integrated operations, century of pharmaceutical expertise, and balanced portfolio approach. Key advantages include established European presence, rare disease capabilities, and comprehensive value chain integration.